elm-2: promising safety and efficacy of odronextamab in r/r dlbcl
Published 8 months ago • 112 plays • Length 4:02Download video MP4
Download video MP3
Similar videos
-
2:43
interim analysis of the elm-2 study: odronextamab in patients with r/r follicular lymphoma
-
0:43
elm-2: qol and orr outcomes of odronextamab treatment for r/r fl
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
2:01
elm-2 trial: using ctdna and mrd to measure odronextamab outcomes in dlbcl and fl
-
1:51
what do the elm-2 results tell us about the efficacy of odronextamab for r/r dlbcl?
-
2:36
safety and preliminary efficacy of elotuzumab and belantamab mafodotin in patients with r/r myeloma
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
2:15
safety and efficacy of astx727 in patients with cmml from phase ii and phase iii ascertain studies
-
43:42
easl studio - s2 e17 - easl haemochromatosis guidelines 2022
-
9:41
the i4mds consortium and immune monitoring in mds
-
1:39:00
haemodynamic management in covid-19 patients
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
5:04
primary analysis of the elm-2: odronextamab in heavily pretreated r/r fl
-
1:22
safety and efficacy of cesnicabtagene autoleucel (ari0002h) for r/r mm
-
1:26
preclinical safety and efficacy of cd123-nk cell engager in r/r aml
-
5:04
efficacy and safety of m-pola for r/r b-cell nhl
-
1:06
epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:43
updates on the use of bispecific antibodies in mcl & the need for more studies in this space